


Supplemental Materials



Supplemental Figure S1. Quantified glucose and proliferation assays of single and combination therapy response. The mean percent GFP fluorescence, measured 96 hours post-treatment (A) and bioluminescence quantification of 2-deoxyglucose uptake, recorded 48-hours post-treatment (B) suggest varying glucose uptake in treated groups. Baseline mean percent GFP fluorescence (C) and 48-hours post-treatment (D) denote a consistent seeding density initially, followed by slight yet insignificant decreases observed 48-hours post-treatment. The mean percent GFP fluorescence taken 96-hours post-treatment (E) and the 48-hours post-treatment fluorescence of 5-ethynyl-2'-deoxyuridine (EdU) uptake (F) signifies a decrease in proliferation in the groups treated with trastuzumab and combination therapies. All groups were normalized to mean of control for ease of comparison. (* indicates p values of ≤ 0.05 , ** $p \leq 0.01$)